RhumbLine Advisers’s Integra LifeSciences IART Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$3.08M Sell
171,265
-25,431
-13% -$356K ﹤0.01% 1715
2026
Q1
$1.85M Buy
196,696
+4,773
+2% +$52.4K ﹤0.01% 1899
2025
Q4
$2.38M Sell
191,923
-9,877
-5% -$131K ﹤0.01% 1770
2025
Q3
$2.89M Sell
201,800
-1,357
-0.7% -$18.6K ﹤0.01% 1711
2025
Q2
$2.49M Buy
203,157
+9,822
+5% +$143K ﹤0.01% 1770
2025
Q1
$4.25M Sell
193,335
-7,599
-4% -$179K ﹤0.01% 1441
2024
Q4
$4.56M Sell
200,934
-6,726
-3% -$147K ﹤0.01% 1470
2024
Q3
$3.77M Sell
207,660
-9,459
-4% -$219K ﹤0.01% 1568
2024
Q2
$6.33M Buy
217,119
+17,628
+9% +$523K 0.01% 1263
2024
Q1
$7.07M Sell
199,491
-12,169
-6% -$487K 0.01% 1234
2023
Q4
$9.22M Sell
211,660
-12,790
-6% -$503K 0.01% 1102
2023
Q3
$8.57M Sell
224,450
-4,328
-2% -$182K 0.01% 1065
2023
Q2
$9.41M Sell
228,778
-5,277
-2% -$254K 0.01% 1040
2023
Q1
$13.4M Sell
234,055
-2,342
-1% -$132K 0.02% 819
2022
Q4
$13.3M Buy
236,397
+11,781
+5% +$600K 0.02% 795
2022
Q3
$9.52M Buy
224,616
+8,524
+4% +$437K 0.01% 910
2022
Q2
$11.7M Buy
216,092
+16,421
+8% +$986K 0.02% 823
2022
Q1
$12.8M Sell
199,671
-3,972
-2% -$262K 0.02% 834
2021
Q4
$13.6M Buy
203,643
+4,237
+2% +$287K 0.02% 807
2021
Q3
$13.7M Sell
199,406
-4,422
-2% -$312K 0.02% 788
2021
Q2
$13.9M Sell
203,828
-2,510
-1% -$177K 0.02% 810
2021
Q1
$14.3M Sell
206,338
-2,273
-1% -$154K 0.02% 774
2020
Q4
$13.5M Buy
208,611
+1,822
+0.9% +$98K 0.02% 750
2020
Q3
$9.77M Sell
206,789
-5,614
-3% -$267K 0.02% 790
2020
Q2
$9.98M Buy
212,403
+2,748
+1% +$135K 0.02% 773
2020
Q1
$9.37M Buy
209,655
+16,953
+9% +$890K 0.02% 692
2019
Q4
$11.2M Sell
192,702
-393
-0.2% -$23.4K 0.02% 763
2019
Q3
$11.6M Sell
193,095
-1,419
-0.7% -$84.5K 0.02% 708
2019
Q2
$10.9M Sell
194,514
-12,408
-6% -$639K 0.02% 730
2019
Q1
$11.5M Buy
206,922
+142
+0.1% +$7.23K 0.02% 698
2018
Q4
$9.33M Buy
206,780
+53,258
+35% +$2.92M 0.02% 750
2018
Q3
$10.1M Sell
153,522
-2,689
-2% -$167K 0.02% 676
2018
Q2
$10.1M Sell
156,211
-4,874
-3% -$302K 0.02% 681
2018
Q1
$8.91M Buy
161,085
+2,794
+2% +$146K 0.02% 716
2017
Q4
$7.58M Buy
158,291
+22,293
+16% +$1.09M 0.02% 826
2017
Q3
$6.87M Buy
135,998
+5,136
+4% +$264K 0.01% 847
2017
Q2
$7.13M Sell
130,862
-1,739
-1% -$83K 0.02% 806
2017
Q1
$5.59M Buy
132,601
+32,867
+33% +$1.4M 0.01% 935
2016
Q4
$4.28M Buy
99,734
+7,160
+8% +$291K 0.01% 1011
2016
Q3
$3.82M Buy
92,574
+6,672
+8% +$280K 0.01% 1034
2016
Q2
$3.43M Sell
85,902
-11,014
-11% -$396K 0.01% 1021
2016
Q1
$3.26M Buy
96,916
+6,320
+7% +$197K 0.01% 1077
2015
Q4
$3.07M Buy
90,596
+5,640
+7% +$176K 0.01% 1100
2015
Q3
$2.53M Sell
84,956
-8,357
-9% -$261K 0.01% 1186
2015
Q2
$2.57M Sell
93,313
-1,591
-2% -$42.4K 0.01% 1238
2015
Q1
$2.39M Buy
94,904
+5,444
+6% +$129K 0.01% 1280
2014
Q4
$1.98M Sell
89,460
-122
-0.1% -$2.47K 0.01% 1352
2014
Q3
$1.82M Buy
89,582
+122
+0.1% +$2.43K 0.01% 1383
2014
Q2
$1.72M Buy
89,460
+6,490
+8% +$121K 0.01% 1482
2014
Q1
$1.56M Sell
82,970
-929
-1% -$17.9K ﹤0.01% 1507
2013
Q4
$1.64M Buy
83,899
+636
+0.8% +$11.7K ﹤0.01% 1493
2013
Q3
$1.37M Sell
83,263
-1,882
-2% -$30.2K ﹤0.01% 1567
2013
Q2
$1.27M Buy
+85,145
New +$1.25M ﹤0.01% 1605

Other funds holding IART

RhumbLine Advisers's IART Position: Q2 2026 in Review

RhumbLine Advisers reduced its Integra LifeSciences (IART) stake by 13% in Q2 2026, selling an estimated $356K and leaving 171,265 shares worth $3.08M. The position accounts for ﹤0.01% of the portfolio, ranked #1715.

RhumbLine Advisers first reported a position in IART in Q2 2013 and has held it in 53 quarters since. The position peaked at $14.3M in Q1 2021. 212 funds tracked by Wall St. Rank hold IART as of Q2 2026.

  • RhumbLine Advisers held 171,265 shares of Integra LifeSciences worth $3.08M as of Q2 2026.
  • RhumbLine Advisers sold 25,431 Integra LifeSciences shares in Q2 2026, an estimated $356K.
  • Integra LifeSciences made up ﹤0.01% of RhumbLine Advisers's portfolio in Q2 2026, its #1715 holding.
  • RhumbLine Advisers first reported a position in Integra LifeSciences in Q2 2013 and has held it in 53 quarters since.
  • RhumbLine Advisers's Integra LifeSciences position peaked at $14.3M in Q1 2021.
  • 212 funds tracked by Wall St. Rank held Integra LifeSciences as of Q2 2026.

Based on RhumbLine Advisers's 13F filing for Q2 2026, filed 12 Aug 2026.